Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $16.57.

OCUL has been the subject of several research reports. Robert W. Baird dropped their price objective on shares of Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Thursday, August 8th. Scotiabank assumed coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $14.00 target price on shares of Ocular Therapeutix in a report on Wednesday, October 16th.

Institutional Trading of Ocular Therapeutix

Hedge funds have recently modified their holdings of the stock. Atlas Capital Advisors LLC acquired a new position in Ocular Therapeutix during the 2nd quarter worth approximately $34,000. Amalgamated Bank raised its position in shares of Ocular Therapeutix by 37.9% during the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 1,481 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 1,015 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in Ocular Therapeutix in the 3rd quarter valued at $70,000. Finally, Algert Global LLC bought a new stake in Ocular Therapeutix during the 2nd quarter valued at $69,000. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Stock Performance

OCUL stock traded down $0.14 during mid-day trading on Friday, hitting $10.39. The stock had a trading volume of 822,024 shares, compared to its average volume of 1,325,190. The firm has a fifty day simple moving average of $9.52 and a 200 day simple moving average of $7.65. Ocular Therapeutix has a 52 week low of $2.00 and a 52 week high of $11.77. The company has a debt-to-equity ratio of 0.18, a current ratio of 16.64 and a quick ratio of 16.55.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.04). The firm had revenue of $16.40 million for the quarter, compared to analyst estimates of $15.85 million. Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The firm's revenue for the quarter was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. On average, equities research analysts expect that Ocular Therapeutix will post -1.02 EPS for the current fiscal year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.